Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1st Annual Mental Health Conference. The conference is being held at the Lotte New York Palace Hotel and virtually from June 27–28, 2022.
The presentation will be available to view on-demand beginning at 7:00 AM ET on Monday, June 27, 2022 through the H.C. Wainwright conference portal and on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com. A webcast recording will be archived on Aptinyx’s website for 30 days following the event.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005388/en/
Investor and Media Contact:
email@example.com or firstname.lastname@example.org